Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.
Veryan Medical announces multimillion-euro investment in Galway operation
6th April 2021 - Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent.
16th Dec 2020 - Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study by John H. Rundback MD at NJ Endovascular & Amputation Prevention, NJ.
2nd September 2020 - Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.